Investigational drug · Phase 3
JYP0322
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non Small Cell Lung Cancer, NSCLC (Advanced Non-small Cell Lung Cancer).
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "JYP0322"
First trial start
2025
Sep 23, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JYP0322", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non Small Cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "JYP0322" as an intervention, largest first.
- A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung CancerPivotal-lookingNot yet recruiting
Guangzhou JOYO Pharma Co., LtdIndustry
NCT07816380 · 216 participants (planned) · Start Oct 30, 2026 · Primary completion Dec 30, 2028
Drug: JYP0322 Tablets; Crizotinib Capsules · For: NSCLC (Advanced Non-small Cell Lung Cancer)
- JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs.Pivotal-lookingNot yet recruiting
Guangzhou JOYO Pharma Co., LtdIndustry
NCT07154368 · 207 participants (planned) · Start Sep 23, 2025 · Primary completion Oct 31, 2027
Drug: Pemetrexed injection; Cross-over to JYP0322 and 1 more · For: Non Small Cell Lung Cancer
Guangzhou JOYO Pharma Co., LtdIndustry
NCT06128148 · 101 participants (planned) · Start May 4, 2022 · Primary completion Jun 30, 2026
Drug: JYP0322 50 mg qd; JYP0322 100 mg qd and 5 more · For: Protein Kinase Inhibitors; Other Protocol Specified Criteria; Lung Neoplasms and 1 more
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1G2032R resistance mutation in NSCLC: The first-in-human phase 1 trial.
Ma Y, Xue J, Gao F, et al. · Cancer Cell 2026
Also in development for Non Small Cell Lung Cancer
- SerplulimabHLX10, HLX43Phase 325 trials
Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage
- ZimberelimabAB122, GS-0122Phase 312 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- DomvanalimabAB154, GS-0154Phase 310 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- SI-B001Phase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- TucidinostatChidamide, HBI-8000Phase 39 trials
Chipscreen Biosciences, Ltd. · Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy, Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
- LBL-007AlcestobartPhase 38 trials
BeOne Medicines (BeiGene) · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer
- aglatimagene besadenovecCAN-2409, AdV-tkPhase 35 trials
Candel Therapeutics, Inc. · Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.